Identifying Patient Candidates for IL-1 Inhibition: Lessons From Real-World Cases - 22/12/15

Doi : 10.1016/S1297-319X(15)30004-X

Annalina Avram ^a, Cátia Duarte ^b, Maria José Santos ^c,ⁱ, Charalampos Papagoras ^d, Konstantinos Ritis ^e, Roberto Scarpioni ^f, Wolfgang A. Schmidt ^g,^⁎ , Panagiotis Skendros ^h

^a Medical Doctor; Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin – Buch, Berlin, Germany

^b Rheumatologist, Rheumatology Department, Centro Hospitalar, Universitario de Coimbra, Coimbra, Portugal

^c Medical Doctor, Department of Rheumatology, Hospital Garcia de ‘Orta, Lisbon, Portugal

^d Rheumatologist, First Department of Internal Medicine and Laboratory of Molecular Hematology, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece

^e Professor of Internal Medicine, First Department of Internal Medicine and Laboratory of Molecular Hematology, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece

^f Head, Department of Nephrology and Dialysis, Ospedale AUSL “Guglielmo da Saliceto”, Piacenza, Italy

^g Deputy Director, Immanuel Krankenhause Berline Medical Centre for Rheumatology Berlin – Buch, Berlin, Germany

^h Assistant Professor of Internal Medicine, First Department of Internal Medicine and Laboratory of Molecular Hematology, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece

ⁱ University Hospital of Alexandroupolis, Alexandroupolis, Greece

^* Corresponding author Corresponding author

Abstract

A subgroup of patients with gouty arthritis have a chronic recurring form that is particularly difficult to treat. Such patients experience repeated flares and often have abundant tophi. Many also have underlying comorbidities, such as renal impairment, cardiovascular disease, gastrointestinal disorders, obesity, and hypertension, which contraindicate the use of standard anti-inflammatory medications. Five patients with difficult to treat gouty arthritis who were either candidates and/or treated with anti-IL therapy are described.

Le texte complet de cet article est disponible en PDF.

Keywords : Anakinra, Anti-IL-1β therapy, Canakinumab, Gouty arthritis, Tophaceous gout

Export

Vol 82 - N° S1

P. eS17-eS29 - octobre 2015 Retour au numéro

Article précédent

Canakinumab for the Patient With Difficult-to-Treat Gouty Arthritis: Review of the Clinical Evidence
Thomas Bardin

| Article suivant

The Way Forward: Practical Clinical Considerations for the Use of Canakinumab in Patients With Difficult-to-Treat Gouty Arthritis
Thomas Bardin, Martinus A.F.J. van de Laar

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Identifying Patient Candidates for IL-1 Inhibition: Lessons From Real-World Cases - 22/12/15

Abstract

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL